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Summary
  The aim of this paper is to give a concise description of hyperthermia and a brief 
review of its clinical applications. Hyperthermia (HT, thermal therapy) is thought 
to be one of the cancer therapies and is considered to be an artiﬁ cial way of in-
creasing the body tissue temperature by delivering heat obtained from external 
sources to destroy cancerous cells or prevent their further growth. The ﬁ rst prin-
ciples of hyperthermic biology are presented. The phenomena of thermotoler-
ance and radiosensitization are brieﬂ y described, as well as the concept of ther-
mal dose delivered to the tissues.
  Three main clinical applications of HT are presented. They include local, region-
al or part-body HT and whole-body HT that deliver heat to localized, advanced 
or deep-seated and disseminated malignancies, respectively, depending on loca-
tion, depth and staging of the tumour. Energies used to apply heat to the tumour 
include microwaves, radiofrequency energy, ultrasound, infrared radiators and 
different kinds of hot sources (hot water, ferromagnetic seeds, nanoparticles, re-
sistive implants). General indications for each HT subtype and possible combi-
nations of HT with other cancer treatment modalities are presented.
  Substantially, HT is used as an adjuvant therapy and in such a role it is being eval-
uated in many clinical randomized trials throughout the scientiﬁ c medical cen-
tres. Their ﬁ rst preliminary results are already available, but still time is needed 
to produce ﬁ rm conclusions and strict indications for hyperthermia treatment.
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DEFINITION OF HYPERTHERMIA
Hyperthermia (HT, thermal therapy, thermother-
apy) is thought to be one of the cancer therapies 
amongst surgery, radiation therapy, chemothera-
py, gene and immunotherapy. It is a natural or ar-
tiﬁ cial phenomenon that involves increasing the 
temperature of the body or a particular region of 
it over the threshold temperature set at a partic-
ular moment by the thermoregulation system of 
an organism [1–3]. In the ﬁ eld of oncology HT 
is considered to be an artiﬁ cial way of increasing 
the body tissue temperature by delivering heat ob-
tained from external sources to destroy cancerous 
cells or prevent their further growth. Hyperthermia 
is mostly identiﬁ ed with a range of temperatures 
from 40 to 48°C or similar maintained at a treat-
ed site for a period of one hour or more [4–7]. 
Because of the results that high temperature may 
produce in tissues, one can refer to use of temper-
atures >50°C as coagulation, 60 to 90°C as ther-
mal ablation, >200°C as charring [2,8].
FIRST PRINCIPLES OF HYPERTHERMIA BIOLOGY
High temperatures, as has been shown in many 
research studies [6], cause direct damage to can-
cerous cells themselves and also sensitize them to 
other treatment modalities (radiotherapy, chem-
otherapy, gene therapy and immunotherapy) 
with usually minimal or no injury to normal tis-
sues [4,7,9–11]. Accordingly, HT is mainly used 
as an adjuvant therapy, not as a sole one [2,5,9]. 
For instance, applying HT weekly, concomitant-
ly with radiation, results in faster tumour regres-
sion rate than radiation alone [12] (Figure 1). 
HT kills cells itself, implicates radiotherapy by 
inducing reoxygenation, increases delivery of li-
posomally encapsulated drugs [11,13] and mac-
romolecules such as monoclonal antibodies or 
polymeric peptides, enhances cellular effects of 
chemotherapeutics and augments immune re-
actions against the tumour due to thermotoler-
ance mediated by heat shock proteins (HSPs) 
[14–16].
Thermotolerance is a general phenomenon re-
ferred to as transient resistance to additional 
heat stress, thus making it impractical to apply 
two different HT sessions with an interval short-
er than 48–72 hours, until the resistance decays 
to a negligible level [4,7,10].
On the other hand, thermotolerance does not re-
ally affect radiosensitization [17] and, what is cru-
cial, may be avoided by exposure of the tumour 
to temperatures over 43°C (optionally, step-down 
heating). The latter, unfortunately, is quite difﬁ -
cult to achieve in the clinic [4,10].
Killing cells depends on the duration of heat-
ing and high temperature levels achieved dur-
ing particular treatment sessions. The higher the 
temperature and the longer time that heat is de-
livered to the tumour, the stronger the lethal ef-
fect and the less thermotolerance is induced in 
it. Brieﬂ y, protein is a predominant target of HT 
[9,18]. Denaturating intracellular proteins desta-
bilize cellular membranes, cytoskeleton, enzymes, 
signal transduction, macromolecular synthesis 
and cell nucleus (by interfering with DNA repair 
systems). Temperature elevated above the phys-
iological level results in changes in blood ﬂ ow, 
vascular permeability and tumour oxygenation 
[19,20]. The ﬁ nal effect of the above is necrotic 
or apoptotic death of preheated cells or their sen-
sitization to ionizing radiation or chemotherapy 
[5,10,18,21]. It is worth noticing that cells in the 
S-phase are the most sensitive to thermal therapy 
and the least sensitive to radiation [4,7].
Environmental and vascular conditions are impor-
tant as well. Damage to cancerous cells is promot-
ed by chronic hypoxia, decreased pH, deprivation 
of nutrients and poor cooling, which are caused 
by pathological microvasculature within the tu-
mor [7]. In general, the mentioned conditions 
are not seen in normal tissues which are not se-
riously affected by thermal treatment (Figure 2). 
On the basis of an Arrhenius plot (an isoeffect 
plot presenting the logarithm of the slope of cell 
survival curves as a function of temperature) one 
can state that there is a breakpoint, estimated to 
be about 43°C, over which increasing the tem-
perature by 1°C results in doubled cellular death 
rate [4,7,10].
THERMAL DOSE
As for now CEM 43°C T90 (cumulative equivalent 
minutes at a standard targeted treatment temper-
ature of 43°C obtained within 90% of the tumour 
volume) appears to be the most useful dosimet-
ric parameter in clinical research [1,22]. 10 CEM 
43°C T90 is suggested as a goal of the treatment. 
This can be explained by the fact that heating a 
particular tumour and delivering at least 43°C 
to 90% of its volume for cumulative (in multiple 
treatments) ≥10 minutes corresponds to doubling 
of the probability for complete response and du-
ration of response to hyperthermia and radiother-
apy versus radiotherapy alone [23]. Simplifying 
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the above, the higher the minimum temperatures 
obtained in the tumour, the better the clinical 
outcome achieved [24–26]. RTOG guidelines in 
force precisely describe the rules of thermome-
try necessary for CEM calculations and assurance 
of hyperthermia quality [27]. By deﬁ nition, ther-
mometry in tumours is invasive, and thus con-
nected with particular complications.
Some ongoing investigations are targeted at de-
veloping magnetic resonance imaging (MRI) as 
a tool of non-invasive thermometry [28–31].
METHODS OF HYPERTHERMIA
There appear to be three main clinical meth-
ods of high temperature application depending 
on location, depth and staging of the tumour. 
Local, regional and whole-body hyperthermia 
deliver heat to localized, advanced or deep seat-
ed and disseminated malignancies, respective-
ly [1,5,6,9,11,32–34] (see Table 1). Energies 
used to apply heat to the tumour include mi-
crowaves (in the range of wavelengths from 433 
to 2450MHz), radiofrequency (ranging from 
Figure 1. Hyperthermia added to radiation therapy and its 
enhancing infl uence on tumour regression in an example of 
malignant melanoma [12].
Figure 2. Mechanism of overheating the tumour. In normal tissue 
(above) blood vessels dilate when physiologically or artifi cially 
heated, which causes increase in blood fl ow through the region 
and decreases its temperature. In the tumour (below), on the 
other hand, pathologic vessels are not able to dilate, some of 
them collapse, so delivered heat is not reduced by blood fl ow and 
intratumoural temperature increases.
Types of hyperthermia Type/site of tumour Clinical applications Types of energy/equipment
Local HT:
– superfi cial
– intracavital
– intraluminal
– interstitial
Superfi cial tumours
Intracavital tumours
Intraluminal tumours
Intracranial tumours
Head & neck cancers
Locally advanced or recurrent 
breast cancer
Malignant gliomas
Rectal cancer
Oesophageal cancer
Soft tissue sarcomas
Microwaves (MW)
Radiofrequency (RF)
Ultrasound (US)
Hot sources: 
– Hot water perfusion
– Resistive wire implants
– Ferromagnetic implants
– Nanoparticles
Regional/Part-body HT:
– abdominal
– pelvic
– limbs
Deep seated tumours
Locally advanced tumours
Cervical cancer
Rectal cancer
Bladder cancer
Prostate cancer
Soft tissue sarcoma
Ovarian cancer
Mesothelioma
Peritoneal carcinomatosis
Whole-body HT Disseminated/metastatic diseases Malignant melanoma
Recurrent soft tissue sarcomas
Ovarian cancer
Infrared radiators
Hot water blankets
Thermal chambers
Table 1. Subtypes of hyperthermia, examples of clinical applications and types of energy delivered to tumours.
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100KHz to 150MHz), ultrasound, hot water per-
fusion (tubes, blankets), resistive wire implants, 
ferromagnetic seeds, nanoparticles, and infrared 
radiators [4,9,35] (Figure 3).
LOCAL HYPERTHERMIA
Local hyperthermia is dedicated to rather small 
tumours (≤3 cm up to 5–6 cm in the longest di-
ameter) [4,5,36–38] located superﬁ cially or with-
in an accessible body cavity such as the rectum 
or oesophagus. Superﬁ cial, interstitial, intralu-
minal or intracavital applicators can be applied 
and, most commonly, microwaves, radio waves 
or ultrasound are used to deliver heat to the tu-
mours. Local techniques enable heating of small 
cancerous areas with sufﬁ cient sparing of normal 
tissues. Prevention of side effects during hyper-
thermia sessions consists of concomitant cooling 
using water boluses whose purpose is to maintain 
the temperature of the skin at a level of about 
37°C and to ensure electromagnetic coupling of 
the applicator to the tissue. This results in less 
blistering and rare burning of the skin.
Tumours located in the skin or just below can be 
heated with superﬁ cial applicators or antennas 
(accessible in different forms of waveguide, spi-
ral, current sheet or compact applicators, avail-
able commercially) emitting a particular type of 
energy, placed directly in or near the area of in-
terest (Figures 4,5). To gather necessary infor-
mation about gained temperature, implantation 
of tubes or needles into anaesthetized tumour 
tissue is necessary. They enable the insertion of 
tiny thermometers (e.g. Bowman or ﬁ bre optic 
probes) for temperature measurements. Proper 
positioning is sometimes assured by ultrasonog-
raphy or computed tomography [6].
Natural oriﬁ ces of human body cavities can be 
the way of intracavital or intraluminal hyperther-
mia applications delivering heat directly into the 
prostate (urethra, rectum), rectal cancer, vagina, 
cervix or oesophagus.
Finally, there is a technique for heating tumours 
interstitially. It is dedicated to the spectrum of 
tumours able to be treated with brachytherapy 
Figure 3. An example of equipment for superfi cial and interstitial 
hyperthermia (BSD 500 hyperthermia system) operating on 
microwaves of 915MHz.
Figure 4. Superfi cial MW hyperthermia of malignant melanoma of 
the skin. Hyperthermia used concomitantly with HDR brachytherapy. 
The small MA 151 applicator is used, BSD 500 hyperthermia 
system.
Figure 5. Superfi cial hyperthermia in management of skin 
metastases of ovarian cancer, concomitant with chemotherapy. The 
largest MA 120 superfi cial applicator is used, BSD 500 hyperthermia 
system.
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(head and neck tumours, prostate cancer, breast 
cancer or brain malignancies). Tiny microwave 
antennas, radiofrequency electrodes, ultrasound 
transducers, heat sources or laser ﬁ bres are insert-
ed into the tumour tissue via brachytherapy ap-
plicators to be used for heating up to 2 hours be-
fore or just immediately after radiation (Figure 6). 
Like brachytherapy, interstitial hyperthermia is 
an invasive procedure and is suitable for lesions 
not larger than about 5cm. The method demands 
an array of applicators to be implanted under lo-
cal or, sometimes, general anaesthesia (Figure 7). 
Some of them are used for inserting hyperther-
mia devices, while the rest are necessary for inter-
stitial thermometry, especially between the anten-
nas (for temperature mapping and to avoid hot 
spots). Some authors put thermometers on the 
skin above the tumour, too [9]. The distance be-
tween antennas should not exceed 1 to 2cm be-
cause of the steep radial decrease in power dep-
osition and vascular perfusion that interacts with 
the temperature rise in the heated tissue.
Among interstitial hyperthermia techniques, ra-
diofrequency ablation should be noted as well. 
Thermoablation uses radio waves to raise temper-
ature within the tumour to over 50°C for more 
than 4 to 6 minutes or for >512 CEM 43°C, and 
causes vascular stasis, cellular coagulation and tis-
sue necrosis. This method is able to destroy small 
focal tumours located within the liver, lung, kid-
ney or bones [8,39–43].
There is also a new cancer therapy using magnetic 
nanoparticles for thermal treatment. In this meth-
od nanoparticles of iron oxide are injected direct-
ly into the tumour tissue and subsequently heated 
using a magnetic ﬁ eld. This provides an opportu-
nity to heat tumours situated in deep body regions 
such as the skull (recurrent glioblastoma) or pel-
vis (prostate and cervical carcinoma) [35].
REGIONAL HYPERTHERMIA
Regional or part-body hyperthermia is a term for 
heating large parts of the body, e.g. abdominal 
cavity, particular organs or limbs. Most often it is 
devoted to treating advanced tumours situated 
in the major and minor pelvis, abdomen (cervi-
cal, prostate, bladder, colorectal and ovarian car-
cinomas) or thighs (soft tissue sarcomas). Three 
main approaches can be listed: deep-seated tu-
mours heated with external applicators, limbs or 
organs heated by means of thermal perfusion, 
and continuous hyperthermic peritoneal per-
fusion (CHPP).
Common external applicators consist of coher-
ent arrays of dipole antenna pairs positioned 
in a ring pattern around the patient. The an-
tennas emit microwave or radiofrequency en-
ergy to be focused in a cancerously altered part 
of the body. With such equipment selected an-
atomical regions can be heated up to 41–42°C 
and this temperature is limited by power depo-
sition in surrounding tissues. Phase and ampli-
tude of each antenna (radiating in a range of 
70 to 150MHz) can be controlled in regard to 
generated SAR distribution. SAR (speciﬁ c ab-
sorption rate) is a physical parameter used to 
describe the interaction between electromag-
netic ﬁ eld and matter. Two other deep-heat-
ing methods involve capacitive and inductive 
techniques, both operating with radiofrequen-
cy sources [1,4,44,45]. In recent years research-
ers have made a lot of attempts to develop plan-
ning systems and treatment monitoring systems 
useful for deep regional hyperthermia, most of-
ten taking advantage of magnetic resonance to-
mography, which can be helpful in noninvasive 
recording of tissue temperature and perfusion 
[1,28,46–48].
Figure 6. Interstitial applicators for MW hyperthermia used in BSD 
500 systems. The distal 4.5 cm are used for heating the tissues.
Figure 7. Interstitial hyperthermia in a radical treatment of right 
breast cancer – concomitantly with HDR brachytherapy boost 
after teleradiotherapy. Five hyperthermia applicators and two 
thermometers are inserted into the elastic breast applicators.
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Malignancies affecting arms or legs (e.g. melano-
ma) or some organs (liver, lung) can be treated 
with regional perfusion. The procedure consists 
in bypassing a large supplying artery of a limb or 
organ and a limb- or organ-draining vein in order 
to deliver heat to the drained blood in an extra-
corporeal way. This method brings less systemic 
side effects in comparison with whole-body hyper-
thermia and is often administered with concom-
itant chemotherapy in cases of limb melanomas, 
soft tissue sarcomas of extremities and liver ma-
lignancies [5,49–51].
Continuous hyperthermic peritoneal perfusion 
(CHPP) or, with the addition of chemotherapeu-
tic agents, hyperthermic intraperitoneal chemo-
therapy (HIPEC) are treatment modalities used 
to deal with cancers disseminated within the ab-
dominal cavity. There can be listed peritoneal 
carcinomatosis of unknown origin, multifocal 
ovarian or colorectal metastases, mesothelio-
ma and stomach cancer. The therapeutic strat-
egy consists of resection of the primary tumour 
and cytoreduction of its peritoneal metastases, 
as well as liver metastases, in some cases. CHHP 
or HIPEC is administered perioperatively, deliv-
ering warmed washing ﬂ uid (41.0–42.5°C) with 
or without anticancer drugs to the peritoneal lay-
ers [33,34,52–55].
WHOLE-BODY HYPERTHERMIA
Whole-body hyperthermia (WBH) is a chance 
for patients with metastatic disease such as 
melanoma, soft tissue sarcoma or ovarian can-
cer. Disseminated cancerous cells are thought 
to be destroyed or sensitized to drugs with high 
temperature of the whole organism. To achieve 
that aim (approximately 41.8–42.2°C) thermal 
chambers, hot water blankets or infrared radia-
tors are used, concomitantly with prevention of 
temperature loss and electrolyte ﬂ uids restora-
tion. Depending on subtype of WBH, patients 
demand general anaesthesia or deep sedation 
while heated up to 42.0°C for 60 minutes (ex-
treme WBH) or to 39.5–41.0°C for 3 to 4 hours 
(moderate WBH), respectively. WBH offers the 
most homogeneous thermal distribution, but, 
on the other hand it is related to the greatest 
probability of complications (thermal stress to 
the heart, lungs, liver or brain). Most common-
ly transient diarrhoea, nausea and vomiting are 
observed [4,5,9,15,36,56–58]. It is worth notic-
ing that using WBH in childhood refractory ma-
lignant solid tumours offers an increase in tu-
mour sensitivity to chemotherapy and results in 
better outcome than standard therapeutic ap-
proaches [59].
APPLICATION OF HYPERTHERMIA AMONG OTHER 
ANTICANCER TREATMENT MODALITIES
Hyperthermia is rarely used as a single cancer 
treatment modality and is usually added to ra-
diation therapy, chemotherapy or radiochemo-
therapy, and recently to gene and immunothera-
py [4,5,7,9–11]. All the regimens have the status 
of scientiﬁ c research or clinical trials focusing on 
the treatment of many types of cancer, especially 
those with poor outcome (melanoma, soft tissue 
sarcoma, head and neck cancers, malignancies 
of the brain, lung, breast, cervix, colon, bladder, 
oesophagus and liver) [1,5,6,9,11,32]. Some of 
them have already proved the efﬁ cacy of hyper-
thermia in combined treatment [5,6,9,11,60], 
but others have not [5,6,11]. As for now, hyper-
thermia added to radiotherapy in breast can-
cer, melanoma, glioblastoma, head and neck tu-
mours and cervix cancer signiﬁ cantly improves 
response and survival [61–66].
HT delivered alone or in combination with other 
cancer treatment is generally well tolerated and, 
if the temperature does not exceed 44.0°C, rarely 
affects normal tissues. Higher thermal depositions 
can lead to blistering, burns, pain or necrosis. In 
case of perfusion techniques there may appear 
swelling of the heated tissue, ischaemia due to 
blood clots or bleeding. On the whole, thermal 
side effects are transient [1,5,9,11,67].
Currently, there are a variety of commercially 
available systems for hyperthermia produced by 
different companies or tested in scientiﬁ c insti-
tutions. Despite the fact that there is a strong ra-
tionale for using HT in some clinical situations, 
there is still a lack of strict indications in which 
cases HT should be delivered obligatorily. Many 
clinical trials have to be closed and summarized 
to ﬁ rmly state that hyperthermia is an effective, 
standard cancer treatment. At present, some stud-
ies have to focus on developing improved hyper-
thermia techniques and ﬁ nd solutions for the 
best combinations of concomitant therapies in 
the treatment of different types of cancer.
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